Skip to main content
NIH funding notice RFA-DA-22-040

High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)

Closed on August 2, 2024.

Posted
September 8, 2021
Close date
August 2, 2024
Activity codes
R01
Institutes taking part
NIDA

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

  1. Reissues: PAS-18-915 HIV/AIDS High Priority Drug Abuse Research (R01 Clinical Trial Optional)
  2. 2 steps back: PAS-18-063 HIV/AIDS High Priority Drug Abuse Research (R01 Clinical Trial Optional)
  3. 3 steps back: PAS-16-018 HIV/AIDS High Priority Drug Abuse Research (R01)

Replaced by RFA-DA-25-024.

Who won it before

53 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $37,044,613 in first-year total cost, median $680,840.

Most frequent study sections

  1. NeuroAIDS and other End-Organ Diseases Study Section[NAED]8
  2. Population and Public Health Approaches to HIV/AIDS Study Section[PPAH]5
  3. Behavioral and Social Science Approaches to Preventing HIV/AIDS Study Section[BSPH]4
  4. Special Emphasis Panel[ZDA1 TXT-E (A1)]4
  5. Special Emphasis Panel[ZDA1 TXT-E (A2)]4

Most frequent institutions

  1. YALE UNIVERSITY6
  2. JOHNS HOPKINS UNIVERSITY5
  3. TEMPLE UNIV OF THE COMMONWEALTH2
  4. UNIVERSITY OF BRITISH COLUMBIA2
  5. UNIVERSITY OF CALIFORNIA, SAN FRANCISCO2
Competing awards under RFA-DA-22-040 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2024Effects of Medication for Opioid Use Disorder on Microglial Activation and Neurocognition in People Living with HIV1R01DA060493-01CORLEY, MICHAEL JAYFARHADIAN, SHELLISPRINGER, SANDRA ANNYALE UNIVERSITY, CT$1,213,037ZDA1
2024Assessment of metformin for restoration of immune homeostasis in HIV+ and HIV- individuals with a history of injection drug use1R01DA060692-01A1EATON, ELLEN FLORENCEKOBIE, JAMES JUNIVERSITY OF ALABAMA AT BIRMINGHAM, AL$1,086,368ZDA1
2024Cell-type based epigenomic analysis to identify druggable genes for people living with HIV infection and using cannabis1R01DA061926-01AOUIZERAT, BRADLEY EXU, KEYALE UNIVERSITY, CT$1,032,192ZDA1
2024Cocaine Abstinence or Reduced Use May Retard Alterations in Brain Structure and Function, and Associated Cognitive Changes among African American Cocaine Users with HIV1R01DA058438-01A1LAI, SHENGHANUNIVERSITY OF MARYLAND BALTIMORE, MD$939,459ZDA1
2024Optimizing PrEP Care Delivery through Adaptive Intervention Strategies for Underserved Rural People who Inject Drugs1R01DA061996-01SURRATT, HILARY LUNIVERSITY OF KENTUCKY, KY$667,270ZDA1
2024Next-Generation MEG Imaging for Quantifying Cortical-Subcortical Dynamics in the Context of HIV and Cannabis Use1R01DA059542-01WILSON, TONY WFATHER FLANAGAN'S BOYS' HOME, NE$639,658ZDA1
2024The Effects of Complex Humanitarian Disaster on HIV Care Engagement and Health Outcomes among HIV-Positive People Who Use Drugs in Ukraine1R01DA060590-01MOROZOVA, OLGAOWCZARZAK, JILLJOHNS HOPKINS UNIVERSITY, MD$629,923ZDA1
2024A multidisciplinary approach to integrate HIV prevention services into clinical care settings for people with opioid use disorder1R01DA059503-01A1CHAN, PHILIP ANDREWTAO, JUNMIRIAM HOSPITAL, RI$596,306ZDA1
2024Estimating the direct and indirect effects of a status-neutral person-centric intervention on HIV transmission among PWID in India1R56DA059552-01CLIPMAN, STEVEN J.SOLOMON, SUNIL SUHASJOHNS HOPKINS UNIVERSITY, MD$375,000ZDA1
2023Sorting and Sequencing Latent Reservoirs in HIV+ Opioid Users1R01DA059551-01ABATE, ADAM R.CLARK, IAINMURTHY, NIRENOTT, MELANIE MARIAJ. DAVID GLADSTONE INSTITUTES, CA$1,630,854ZDA1
2023Mitigating the Impact of Stigma and Shame as a Barrier to Viral Suppression Among MSM Living with HIV and Substance Use Disorders1R01DA057298-01A1BATCHELDER, ABIGAIL WINSTONMASSACHUSETTS GENERAL HOSPITAL, MA$799,064ZDA1
2023Computational modeling to evaluate socio-structural interventions for HIV and substance use1R01DA057350-01A1HOTTON, ANNAUNIVERSITY OF CHICAGO, IL$775,680ZDA1
2023Investigate Host Gene Isoforms Contributing to HIV Persistence in Cocaine Users1R01DA059538-01JIANG, WEIZHU, JIANOHIO STATE UNIVERSITY, OH$741,073ZDA1
2023Relationship between methamphetamine use, viral reservoir dynamics and clinical progression in treated HIV infection1R01DA058437-01CARRICO, ADAM WAYNESTEVENSON, MARIOTOOKES, HANSEL EMORYUNIVERSITY OF MIAMI SCHOOL OF MEDICINE, FL$663,951ZDA1
2023Hepatotoxic mechanisms of anti-HIV- and anti-COVID-19 drugs and substance use disorders1R01DA058458-01JI, CHENGUNIVERSITY OF SOUTHERN CALIFORNIA, CA$391,875ZDA1
2022Heavy cannabis use, neurocognition and PrEP care engagement among young Black sexual minority men1R01DA057351-01KEEDY, SARAH KKNOX, JUSTINSCHNEIDER, JOHNUNIVERSITY OF CHICAGO, IL$915,004ZDA1
2022Integrated eHealth for HIV and Substance Use Disorders in Justice-involved Women1R01DA057342-01MEYER, JAIMIEYALE UNIVERSITY, CT$741,989ZDA1
2022Benzodiazepine mediated mechanisms of transcriptional semi-quiescence in discrete myeloid populations1R01DA057337-01GASKILL, PETER JESSEKLASE, ZACHARY ALANDREXEL UNIVERSITY, PA$695,124ZDA1
2022Innovative therapeutic approaches to address excitotoxic CNS/neuronal damage in opioid-neuroHIV comorbidity1R01DA057346-01HAUSER, KURT FKNAPP, PAMELA EVIRGINIA COMMONWEALTH UNIVERSITY, VA$678,736ZDA1
2022Expanding Medication Assisted Therapies in Central Asia1R01DA054851-01A1 · under PAS-18-915ALTICE, FREDERICK LEWISMADDEN, LYNNYALE UNIVERSITY, CT$625,373PPAH
2021Impact of a novel HIV peer navigationand overdose prevention intervention on engagement in the HIV prevention and treatment cascade.1R01DA053184-01A1 · under PAS-18-915SHERMAN, SUSAN G.JOHNS HOPKINS UNIVERSITY, MD$794,472ZRG1
2021Risk Factors for AIDS among Persons Who Inject Drugs: HIV and COVID-192R01DA003574-37A1 · under PAS-18-915DES JARLAIS, DON CMCKNIGHT, COURTNEYNEW YORK UNIVERSITY, NY$792,422PPAH
2021Stigma and Substance Use as Barriers to PrEP Linkage, Uptake, Adherence, and Persistence among BMSM1R01DA053168-01 · under PAS-18-915EATON, LISA AUNIVERSITY OF CONNECTICUT STORRS, CT$622,614HIBI
2021Modulation of OPRM1 alternative splicing by morphine and HIV-1 Nef1R01DA052284-01A1 · under PAS-18-915CHANG, SULIE L.SARIYER, ILKER KUDRETTEMPLE UNIV OF THE COMMONWEALTH, PA$358,742HVCD
2021The ION+EMI Study: Intermittent Oral Naltrexone enhanced with an Ecological Momentary Intervention for Methamphetamine-using MSM1R01DA053171-01A1 · under PAS-18-915SANTOS, GLENN-MILOUNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA$329,820HIBI
2020Cocaine use, viral suppression and precursors of stroke in HIV infection1R01DA049648-01A1 · under PAS-18-915RILEY, ELISE D.UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA$805,697HCCS
2020A geospatial analysis of hotspots and targeted injection settings pilot intervention for HIV prevention among people who inject drugs in Baltimore, Maryland1R01DA050470-01A1 · under PAS-18-915LATKIN, CARL AJOHNS HOPKINS UNIVERSITY, MD$784,526PPAH
2020Resubmission: Multilevel Strategies & Tailored HIV Prevention & Care for Young Couples who use Alcohol & Other Drugs Across Cape Town1R01DA049612-01A1 · under PAS-18-915BROWNE, FELICIA AMIRACARNEY, TARAWECHSBERG, WENDEE MRESEARCH TRIANGLE INSTITUTE, NC$732,304PPAH
2020Impacts of structural and system-level interventions on HIV/STI and overdose epidemics among SWs2R01DA028648-11 · under PAS-18-915GOLDENBERG, SHIRA MIRIAMSHANNON, KATEUNIVERSITY OF BRITISH COLUMBIA, BC$538,742PPAH
2020HIV-1 Neurotoxicity: Mechanism & Modulation by Cannabinoids2R01DA007304-28A1 · under PAS-18-915THAYER, STANLEY AUNIVERSITY OF MINNESOTA, MN$457,086HVCD
2019Effects of mu-opiate receptor engagement on microbial translocation and residual immune activation in HIV-infected, ART suppressed opioid use disorder patents initiating medication-assisted treatment1R01DA048728-01 · under PAS-18-063METZGER, DAVID SMONTANER, LUIS JWISTAR INSTITUTE, PA$1,248,932HCCS
2019Effects of Mu-opiate receptor engagement on the persistence of HIV-associated activation and viral reservoirs in individuals receiving medication assisted treatment for opioid use disorder1R01DA049666-01 · under PAS-18-915MONTANER, LUIS JWISTAR INSTITUTE, PA$827,942HIVD
2019Elimination of HCV and related liver disease among HIV-infected and -uninfected people who inject drugs1R01DA048063-01 · under PAS-18-063MEHTA, SHRUTI HTHOMAS, DAVID LJOHNS HOPKINS UNIVERSITY, MD$727,804ZRG1
2018Effects of State Laws to Reduce Opioid Diversion on Transitions to Injection Drug Use and HIV/HCV Transmission1R01DA044971-01A1 · under PAS-16-018DICKSON-GOMEZ, JULIA BMEDICAL COLLEGE OF WISCONSIN, WI$652,675ZRG1
2018The impact of naltrexone treatment on opioid-induced immune and viral dysregulation during HIV-infection1R01DA046229-01A1 · under PAS-18-063LANCIONI, CHRISTINA LOUISEOREGON HEALTH & SCIENCE UNIVERSITY, OR$415,765NAED
2018Role of miRNAs in Methamphetamine/HIV-mediated Immune Activation1R01DA045568-01A1 · under PAS-16-018HO, WENZHETEMPLE UNIV OF THE COMMONWEALTH, PA$396,250ZRG1
2018Immunomodulation of nicotine in HIV-1Tg rat brain1R01DA046258-01 · under PAS-16-018CHANG, SULIE L.LI, MING DSETON HALL UNIVERSITY, NJ$347,750NAED
2017A Multi-site Multi-Setting RCT of Integrated HIV Prevention and HCV Care for PWID1R01DA045713-01 · under PAS-16-018BRUNEAU, JULIEFEASTER, DANIEL JMETSCH, LISA RCOLUMBIA UNIVERSITY HEALTH SCIENCES, NY$1,322,957ZDA1
2017Expanding Medication Assisted Therapy in Ukraine (ExMAT)2R01DA033679-06 · under PAS-16-018ALTICE, FREDERICK LEWISYALE UNIVERSITY, CT$769,707BSPH
2017Buprenorphine treatment at syringe exchanges to reduce opioid misuse and HIV risk1R01DA044878-01 · under PAS-16-018FOX, AARON DALBERT EINSTEIN COLLEGE OF MEDICINE, INC, NY$721,387BSPH
2017Integrated Behavioral Activation and HIV Risk Reduction Counseling for MSM with Stimulant Abuse1R01DA042805-01A1 · under PAS-16-018MIMIAGA, MATTHEW JAMESSAFREN, STEVEN ABROWN UNIVERSITY, RI$714,427ZDA1
2017Testing an integrated bio-behavioral primary HIV prevention intervention among high-risk people who use drugs1R01DA044867-01 · under PAS-16-018COPENHAVER, MICHAELUNIVERSITY OF CONNECTICUT STORRS, CT$690,524BSPH
2017HIV/COCAINE NEUROTOXICITY IN FEMALES2R01DA013137-16 · under PAS-16-018BOOZE, ROSEMARIE MMACTUTUS, CHARLES F.UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA, SC$600,321ZRG1
2017Impacts of universal access to HIV/AIDS care among HIV+ injection drug users2U01DA021525-11 · under PAS-16-018MILLOY, M-JUNIVERSITY OF BRITISH COLUMBIA, BC$541,273ZRG1
2017Bivalent Ligands as Chemical Probes to Study Opioid Abuse-enhanced HIV Infection1R01DA044855-01 · under PAS-16-018HAUSER, KURT FZHANG, YANVIRGINIA COMMONWEALTH UNIVERSITY, VA$507,931NAED
2017Primary role of Golgi stress in anti-HIV drug and alcohol abuse-induced hepatotoxicity1R01DA042632-01A1 · under PAS-16-018JI, CHENGUNIVERSITY OF SOUTHERN CALIFORNIA, CA$412,500NAED
2017An ethno-epidemiological study to advance HIV prevention and treatment for PWUD1R01DA043408-01 · under PAS-16-018MCNEIL, RYANSMALL, WILLSIMON FRASER UNIVERSITY, BC$325,817BSPH
2016Impact of smoking and its cessation on systemic and airway immune activation1R01DA042685-01 · under PAS-16-018LIN, NINA H.SPIRA, AVRUM EBOSTON MEDICAL CENTER, MA$827,665NAED
2016OMICs to define impact of cocaine on immunity and HIV persistence in treated HIV infection1R01DA042712-01 · under PAS-16-018SEKALY, RAFICK PIERRECASE WESTERN RESERVE UNIVERSITY, OH$717,500NAED
2016Nanotechnology Based Gene Editing to Eradicate HIV Brain Reservoir in Drug Abusers1R01DA042706-01 · under PAS-16-018KHALILI, KAMELNAIR, MADHAVAN P.FLORIDA INTERNATIONAL UNIVERSITY, FL$680,840NAED
2016Understanding the Role of Cognitive Dysfunction in the Treatment of Nicotine Dependence among HIV-Infected Smokers1R01DA042682-01 · under PAS-16-018ASHARE, REBECCAUNIVERSITY OF PENNSYLVANIA, PA$660,298BSCH
2016Methylome-wide and mQTL analysis of HIV progression in the context of cocaine use1R01DA042691-01 · under PAS-16-018XU, KEYALE UNIVERSITY, CT$468,553ZRG1
2016Extracellular Vesicles and and HIV/cocaine associated cardiopulmonary dysfunction1R01DA042715-01 · under PAS-16-018DHILLON, NAVNEET KAURUNIVERSITY OF KANSAS MEDICAL CENTER, KS$411,434NAED

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

RFA-DA-22-040: High Priority HIV and Substance Use Research (R01 Clinical Trial Optional) | ScienceDex | ConductScience